## Abstract ## BACKGROUND The authors conducted a series of four Phase IβII trials of highβdose and intermediateβdose docetaxel, cisplatin, and 5βfluorouracil (TPF)βbased induction chemotherapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). The chemotherapy regime
Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck
β Scribed by Mamoru Tsukuda; Yasukazu Mikami; Yuji Tanigaki; Hideaki Katori; Choichi Horiuchi; Yoichi Ikeda; Takahide Taguchi; Machiko Ono; Takahumi Yoshida; Yasunori Sakuma; Ken Aikoh
- Publisher
- Springer
- Year
- 2004
- Tongue
- English
- Weight
- 234 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1341-9625
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Patients with locally advanced, inoperable squamous cell carcinoma of the head and neck were offered three courses of cisplatin and 96-h 5-fluorouracil (5-FU) infusion. Subsequent therapy included surgery when feasible, irradiation therapy, and a maintenance program of methotrexate (MTX)-5-FU. Thirt
## Abstract ## Background. Intraoperative manipulation of the tumor during cancer surgery has long been recognized as a source of metastasis and contamination of the surgical wound during tumor removal. We explored the use of intraoperative chemotherapy to minimize the risk of tumor cell implantat
## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi